Multinational pharmaceutical companies are changing logos

one after another

willingness to develop innovative new drugs

Sanofi changes signboards by integrating vaccine-specialty care division

Pfizer will be all-in to mRNA for the first time in 70 years

Organon Korea returns after 13 years of absence with a new logo, "Women's Health" starts anew.

 

Multinational pharmaceutical companies are trying to transform their image with new logos.

 

Pfizer entered the unexplored area of mRNA and changed its logo in about 70 years.

 

Sanofi also emphasized "one Sanofi" as an integrated brand logo.

 

Analysts say that multinational pharmaceutical companies are expressing the spirit of science and innovation with new logos as they jump into areas where it is difficult to develop treatments.

 

Sanofi-Aventis Korea announced on the 15th that it will remove the separate brands attached to each division and merge them into a single brand.

 

Until now, the vaccine division has been called Sanofi Pasteur and the specialty care division has been called Sanofi Genzyme.

 

In the future, Pasteur and Genzyme will be excluded and all will be integrated into "Sanofi." However, the existing corporations divided into Sanofi-Pasture and Sanofi-Aventis are not integrated.

 

Old Sanofi logo (left) and New logo (right)

The intention is to unite distributed brands and present common goals and identities.

 

Founded in 1973, Sanofi has included companies it has acquired, including Sanofi-Synthelabo, Aventis, and Genzyme, in its business team brand names.

 

Then, in 2019, it announced the improvement of the constitution of the new drug pipeline and began to change.

 

It will boldly give up pipelines with poor growth engines such as chronic diseases and invest heavily in new growth fields such as immunity, rare diseases, and nervous system diseases.

 

In other words, Sanofi's four business units ▲ Sanofi Pasteur (vaccine) ▲ Sanofi Genzyme (specialty care) ▲ General Medicine ▲ Consumer Healthcare is a plan to integrate and expand Pasteur and Genzyme.

 

The logo has also been transformed as part of the first brand integration in Sanofi's history.

 

The new shape, which means innovation, adaptation, and growth, has changed the existing logo, which used to form a circle, to a lowercase logo with two purple dots at the beginning and end of the name.

 

The new logo is inspired by the simple yet dynamic nature of the tech industry.

 

The purple dot on S means the starting point for asking the question What if?

 

The purple dot of i is the end point that results in the discovery of innovative solutions.

 

The new logo represents Sanofi's scientific journey from the starting point to the ending point.

 

Sanofi said, "In the future, we will think and move as a company under a new and common purpose and identity," adding, " we hope the new integrated brand unveiled this time will serve as an opportunity to inform employees, partners, medical experts and patients of Sanofi's identity and orientation."

The old Pfizer logo (left) and the new logo (right)

Pfizer, which is improving its constitution to develop innovative new drugs, also introduced a new logo for the first time in 70 years.

 

The pill-shaped oval background, which has been representative of Pfizer, has been boldly discarded.

 

The new logo represents a double helix with two tones of blue bands symbolizing Pfizer.

 

This means that the substance of double helix is revealed by unlocking the original pill form.

 

The logo extending upward conveys an upward movement, and the rotating form means "reversing the old reality for innovation." Pfizer, which planned to spin off its patent expiration division and change its logo, finally selected a design produced by Brooklyn Studio Team in the U.S.

 

Just in time, Pfizer succeeded in transforming its image by introducing the COVID-19 vaccine.

 

Pfizer, which commercialized the mRNA-based vaccine for the first time, has also drastically trimmed its pipeline to suit the new logo.

 

It has begun to develop mRNA-based drugs in earnest.

 

mRNA-based drugs are a new mechanism that has just begun commercialization, and there are still many unexplored areas.

 

Old organon logo (left) and new logo (right)

Organon, which was spun off from MSD, has started to break away from its past image with a new logo.

 

Founded in the Netherlands in 1923, Organon is the place where the early substance of the immuno-cancer drug Keytruda was developed.

 

It has a history of being absorbed into MSD through a merger with Schering-Plough.

 

About 10 years later, it was separated from MSD again and reborn as an independent corporation.

 

Organon, which focused on women's health in the past, focused on three areas: women's health after independence, chronic diseases, and biosimilars.

 

The name Organon Korea is the same, but it changed the logo in the sense of starting anew.

 

Unlike the old logo, which was a turquoise oval band, the new logo has a circular point in green, blue, and sky blue and a scarlet dash pattern forming a geometric pattern.

 

The central dot means women's health, and the surrounding dots indicate that the company is paying attention to various environments that affect women's health.

 

The dash pattern contains a commitment to improving human life, a vision for a healthier life for all women, and a mission to supply meaningful medicines.

 

The geometric pattern created by gathering dots and dashes means that the company's appearance today and its vision for tomorrow communicate and integrate with each other.

 

Organon Korea said, "In the past, Organon Korea has also made a lot of innovations in women's health," adding, "The new Organon Korea will provide new solutions for women's health, which was relatively unmet."